PMID: 7537376Apr 25, 1995Paper

Potent interleukin 3 receptor agonist with selectively enhanced hematopoietic activity relative to recombinant human interleukin 3

Proceedings of the National Academy of Sciences of the United States of America
J W ThomasJ P McKearn

Abstract

A systematic evaluation of structure-activity information led to the construction of genetically engineered interleukin 3 (IL-3) receptor agonists (synthokines) with enhanced hematopoietic potency. SC-55494, the most extensively characterized member of this series, exhibits 10- to 20-fold greater biological activity than recombinant human IL-3 (rhIL-3) in human hematopoietic cell proliferation and marrow colony-forming-unit assays. In contrast, SC-55494 is only twice as active as rhIL-3 in priming the synthesis of inflammatory mediators such as leukotriene C4 and triggering the release of histamine from peripheral blood leukocytes. The enhanced hematopoietic activity of SC-55494 correlates with a 60-fold increase in IL-3 alpha-subunit binding affinity and a 20-fold greater affinity for binding to alpha/beta receptor complexes on intact cells relative to rhIL-3. SC-55494 demonstrates a 5- to 10-fold enhanced hematopoietic response relative to its ability to activate the priming and release of inflammatory mediators. Therefore, SC-55494 may ameliorate the myeloablation of cancer therapeutic regimens while minimizing dose-limiting inflammatory side effects.

References

May 21, 1976·Biochimica Et Biophysica Acta·S Jacobs, P Cuatrecasas
Aug 1, 1989·The Journal of Experimental Medicine·Y KurimotoC A Dahinden
Jan 1, 1986·Annual Review of Immunology·J W Schrader
Mar 1, 1988·The Journal of Clinical Investigation·R J BerensonI D Bernstein
Sep 1, 1994·The Journal of Experimental Medicine·O KanA D Whetton
Mar 29, 1994·Proceedings of the National Academy of Sciences of the United States of America·D X DingD W Golde
Sep 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·O SilvennoinenJ N Ihle
Jan 1, 1993·Cancer Investigation·A Ganser

❮ Previous
Next ❯

Citations

Aug 1, 1997·Protein Science : a Publication of the Protein Society·Y FengC A McWherter
Jan 1, 1997·Stem Cells·T J MacVittie
Oct 23, 1997·Applied Biochemistry and Biotechnology·S MerlinS C Lee
Sep 1, 1996·Trends in Biotechnology·T A McAdamsE T Papoutsakis
Oct 1, 1995·Current Opinion in Biotechnology·P J Hippenmeyer, L E Pegg
Jun 13, 2002·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Heidi Schooltink, Stefan Rose-John
Nov 9, 2001·Biochemical and Biophysical Research Communications·B K KleinJ P McKearn
Feb 17, 2005·Experimental and Molecular Pathology·Vijay K Singh, Virendra S Yadav
Jul 22, 1998·Transfusion Medicine Reviews·G Ramsey
Jun 15, 2004·Molecular Therapy : the Journal of the American Society of Gene Therapy·A Alex HoflingMark S Sands
Aug 3, 1999·Nature Biotechnology·C C ChangP A Patten
Oct 16, 2018·Journal of Cellular Biochemistry·Niroshani Surangika Soysa, Neil Alles
Jan 28, 2018·Nature Communications·Sophie E BroughtonMichael W Parker
Oct 6, 1995·The Journal of Biological Chemistry·P O OlinsJ A Klover
Sep 5, 1997·The Journal of Biological Chemistry·B K KleinJ P McKearn
Jul 15, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J F DiPersioC M Baum
Mar 5, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Razelle Kurzrock
Jan 3, 2021·Cell Biology International·Sahar NajafiNajmaldin Saki

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.